FASN and breast carcinoma: is in breast cancer [96], where the highest FASN expression was found in brain metastases to accommodate the elevated acetate levels produced by upregulated acetyl-CoA synthetase 2 (ACSS2) for FA synthesis [98], whereas the lowest was found in liver metastases, to shift the metabolic phenotype of metastasising cells to become more glycolytic for overcoming the varying hypoxic barriers present in the liver [99].